



ASX Announcement

26 April 2024

Appointment of New Director

Melbourne, Australia, 26 April 2024 – Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), a biotechnology company focused on developing and commercialising innovative pharmaceutical products using its proprietary Tocopheryl Phosphate Mixture (“TPM®”) drug delivery system, is pleased to announce the appointment of Kathy Connell as a Non-Executive Director of the Company, effective 26th of April 2024.

Kathy Connell is an internationally recognised healthcare and lifesciences leader with extensive investment and licensing expertise, with a solid track record of value creating deals across pharmaceuticals, medtech, vaccines consumer and digital healthcare for some of the world's largest companies.

For the past 20 years, Kathy has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, including 12 years at Johnson & Johnson as Senior Director, New Ventures ANZ. During her tenure at Johnson & Johnson and Sanofi, Kathy led external innovation investment, licensing and acquisition across ANZ, executing nearly 100 deals across Australia worth more than \$US1B.

Kathy co-founded Medicines Australia’s Pharmaceutical Australia Inclusion Group (“PAIG”) – a special working group designed to foster diverse and inclusive corporate cultures across the pharmaceutical industries, to enhance social sustainability, responsible business practices and deliver long-term value creation. She was awarded BioMelbourne Network’s Woman of the Year in 2018 for her leadership in supporting Australia's high priority strategic growth sectors of biotech, medtech and pharmaceuticals.

Today Kathy leads Korn Ferry’s Healthcare and LifeSciences practice in Australia as Senior Client Partner and she is also a Non-Executive Director of BioNSW, the peak body for Lifesciences companies and professionals in NSW. Kathy holds various tertiary degrees and qualifications in Applied Science, Psychology, Mediation and Law, as well as being a Graduate of the Australian Institute of Company Directors.

Ms Connell has been offered 3,993,644 sign-on unquoted options (“Options”) to vest in four equal tranches. The exercise price of the Options will be at a 25% premium of 30-day volume weighted average price of AVE’s share price of 24 April 2024. These Options will be issued immediately upon appointment.

Avecho Biotechnology Limited Chair, Dr Greg Collier, said: “As Avecho enters a pivotal Phase III clinical trial with a late stage asset, our ongoing business development and licensing discussions are entering a defining phase of execution. The Board is delighted to welcome a Director of Kathy’s calibre – she will be in a position to leverage significant licensing experience in some of the world’s largest pharmaceutical companies and maximise our chances of securing high value future licensing agreements. This executive appointment is a significant achievement for our Company and we look forward to working closely with Kathy in the years to come.”



Kathy Connell, said: "I have known Avecho for some time, and so am thrilled to join the Board of Directors and contribute to the commercialisation of life-enhancing medicines worldwide. It is an incredible opportunity to help bring innovative treatments to those who need them most, with an immediate focus on the millions of Australians that suffer from insomnia."

The Board formally welcomes Kathy Connell to Avecho Biotechnology Limited and believes that her extensive expertise in the healthcare and medical sciences sector will be a tremendous asset for the Company.

For enquiries, please contact

Dr Greg Collier
Avecho Biotechnology Limited
+61 3 9002 5000
Email: gcollier@avecho.com.au

This announcement is authorised for release to the market by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited (ASX:AVE) develops and commercialises innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM[®] enhanced patches, gels and injectable products for the human health market and is also developing TPM[®] to enhance the feed efficiency and health of livestock.

See more here - <http://avecho.com.au/>